Notice: This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CNAT vs. SBFM, PTPI, MTEM, DRMA, ATNF, CTOR, CMND, NTBL, CYCC, and GRTXShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Sunshine Biopharma (SBFM), Petros Pharmaceuticals (PTPI), Molecular Templates (MTEM), Dermata Therapeutics (DRMA), 180 Life Sciences (ATNF), Citius Oncology (CTOR), Clearmind Medicine (CMND), Notable Labs (NTBL), Cyclacel Pharmaceuticals (CYCC), and Galera Therapeutics (GRTX). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Sunshine Biopharma Petros Pharmaceuticals Molecular Templates Dermata Therapeutics 180 Life Sciences Citius Oncology Clearmind Medicine Notable Labs Cyclacel Pharmaceuticals Galera Therapeutics Conatus Pharmaceuticals (NASDAQ:CNAT) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is CNAT or SBFM more profitable? Sunshine Biopharma has a net margin of -12.82% compared to Conatus Pharmaceuticals' net margin of -52.42%. Sunshine Biopharma's return on equity of -17.89% beat Conatus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% Sunshine Biopharma -12.82%-17.89%-14.25% Which has higher valuation and earnings, CNAT or SBFM? Sunshine Biopharma has higher revenue and earnings than Conatus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.03-$11.39MN/AN/ASunshine Biopharma$24.09M0.12-$4.51M-$150.88-0.02 Which has more volatility & risk, CNAT or SBFM? Conatus Pharmaceuticals has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Does the media favor CNAT or SBFM? In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score. Company Overall Sentiment Conatus Pharmaceuticals Neutral Sunshine Biopharma Neutral Do institutionals and insiders hold more shares of CNAT or SBFM? 15.2% of Conatus Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 11.3% of Conatus Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor CNAT or SBFM? Conatus Pharmaceuticals received 536 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 79.67% of users gave Conatus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformConatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Sunshine BiopharmaOutperform Votes1100.00% Underperform VotesNo Votes SummarySunshine Biopharma beats Conatus Pharmaceuticals on 9 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$663,000.00$6.59B$5.21B$8.86BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-0.074.3563.3213.02Price / Sales0.03357.031,250.4787.30Price / CashN/A53.8240.8736.91Price / Book0.0410.617.196.54Net Income-$11.39M$153.27M$119.54M$226.22M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.02flatN/A-94.1%$663,000.00$21.72M-0.0730Gap UpSBFMSunshine Biopharma0.0948 of 5 stars$2.36+11.3%N/A-90.6%$2.60M$24.09M0.003News CoverageGap UpHigh Trading VolumePTPIPetros Pharmaceuticals2.958 of 5 stars$0.27+3.8%$4.00+1,382.0%-78.7%$2.57M$5.82M0.0020High Trading VolumeMTEMMolecular Templates2.2619 of 5 stars$0.34-10.7%N/A-93.4%$2.50M$57.31M0.0062News CoverageGap UpDRMADermata Therapeutics2.3732 of 5 stars$1.14-0.9%$6.00+427.7%-89.3%$2.35MN/A-0.078Positive NewsATNF180 Life Sciences0.302 of 5 stars$2.25-1.3%N/A-65.1%$2.34MN/A0.007CTORCitius OncologyN/A$0.85-12.3%N/AN/A$2.30MN/A0.00N/ACMNDClearmind Medicine0.1919 of 5 stars$1.33-0.7%N/A-62.7%$2.27MN/A0.00N/ANTBLNotable LabsN/AN/A$7.00+∞N/A$2.24M$313,000.000.0040Gap DownHigh Trading VolumeCYCCCyclacel Pharmaceuticals2.1357 of 5 stars$0.36+2.9%$11.00+2,989.9%-91.5%$2.18M$420,000.000.0014Analyst ForecastGRTXGalera TherapeuticsN/A$0.04flatN/A-71.3%$2.18MN/A0.0030Gap Down Related Companies and Tools Related Companies Sunshine Biopharma Competitors Petros Pharmaceuticals Competitors Molecular Templates Competitors Dermata Therapeutics Competitors 180 Life Sciences Competitors Citius Oncology Competitors Clearmind Medicine Competitors Notable Labs Competitors Cyclacel Pharmaceuticals Competitors Galera Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNAT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
